| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | Napirimus Basic information |
| Product Name: | Napirimus | | Synonyms: | Napirimus;Napirimus [inn];Unii-45081sg6xt;1H-Pyrrole-2-carboxylic acid, 1-methyl-4-(1-naphthalenylcarbonyl)-;Napirimus, 10 mM in DMSO;1-Methyl-4-(naphthalene-1-carbonyl)-1H-pyrrole-2-carboxylic acid | | CAS: | 70696-66-1 | | MF: | C17H13NO3 | | MW: | 279.29 | | EINECS: | | | Product Categories: | | | Mol File: | 70696-66-1.mol |  |
| | Napirimus Chemical Properties |
| Boiling point | 536.6±35.0 °C(Predicted) | | density | 1.25±0.1 g/cm3(Predicted) | | solubility | DMSO: Slightly soluble: 0.1-1 mg/ml | | pka | 3.83±0.41(Predicted) |
| | Napirimus Usage And Synthesis |
| Description | Napirimus is an immunosuppressant.1 It is efficacious and preventative in a rat model of polyarthritis induced by complete Freund’s adjuvant when administered at doses of 200 and 100 mg/kg, respectively. Napirimus is 50 and 90% protective against experimental autoimmune encephalomyelitis (EAE), previously known as allergic encephalomyelitis, in rats when administered at doses of 100 and 400 mg/kg, respectively.WARNING This product is not for human or veterinary use. | | References | [1] Peptides having immunostimulating properties and pharmaceutical compositions containing them[J]. Vaccine, 1983, 1 1: Page 52. DOI: 10.1016/0264-410x(83)90037-3 |
| | Napirimus Preparation Products And Raw materials |
|